ClinicalTrials.gg
CompletedNCT00516438Updated Dec 8, 2010

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

A Phase 1 interventional study of KU-0059436 (AZD2281)(PARP inhibitor) and Topotecan in Malignant Solid Tumors, sponsored by AstraZeneca. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-08.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours

02

Conditions studied

  • Malignant Solid Tumors

Keywords

  • malignant solid tumours
  • Poly(ADP ribose)
  • polymerases
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological or cytological diagnosis of advanced solid tumour for which no suitable effective therapy exists;
  • Evaluable disease
  • Adequate bone marrow, hepatic and renal function

Exclusion criteria

Exclusion Criteria:

  • Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry; major surgery with 4 weeks of entering the study
  • Heavily pre treated patient > 2 previous chemotherapy regimens for disease
  • Co-existing active infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    1

    Topotecan + KU-0059436

    Drug: KU-0059436 (AZD2281)(PARP inhibitor) · Drug: Topotecan

Interventions

06

What researchers measure

Primary outcomes

  1. To establish the maximum tolerated dose (MTD) of KU 0059436 in combination with topotecan

    Time frame: assessed at each visit

Secondary outcomes

  1. To identify the dose limiting toxicity of the combination therapy

    Time frame: assessed at each visit

07

Study locations

3 sites
  • Research Site
    Glasgow, United Kingdom
  • Research Site
    Leicester, United Kingdom
  • Research Site
    Manchester, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Mar 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2007
First posted
Aug 15, 2007
Start
Jul 2007
Primary completionActual
Mar 2009
CompletionActual
Nov 2009
Last update
Dec 8, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00516438
Lead sponsor
AstraZeneca
Collaborators
KuDOS Pharmaceuticals Limited
First posted
Aug 15, 2007
Start date
Jul 2007
Primary completion
Mar 2009
Completion
Nov 2009
Last update
Dec 8, 2010

Study contacts

James Cassidy
principal investigator · Beaston Oncology Centre, Glasgow, UK
James Carmichael, BSc MBChB MD FRCP
study director · KuDOS Pharmaceutical Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion